Northern Trust Corp reduced its holdings in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) by 11.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 357,961 shares of the company's stock after selling 47,597 shares during the quarter. Northern Trust Corp owned 0.78% of Azenta worth $17,898,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Picton Mahoney Asset Management lifted its position in shares of Azenta by 305.7% during the 4th quarter. Picton Mahoney Asset Management now owns 706 shares of the company's stock worth $35,000 after buying an additional 532 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Azenta during the 4th quarter worth $40,000. Covestor Ltd increased its holdings in Azenta by 64.2% in the 4th quarter. Covestor Ltd now owns 2,043 shares of the company's stock worth $102,000 after purchasing an additional 799 shares in the last quarter. KBC Group NV increased its holdings in Azenta by 48.5% in the 4th quarter. KBC Group NV now owns 2,137 shares of the company's stock worth $107,000 after purchasing an additional 698 shares in the last quarter. Finally, Quarry LP acquired a new position in Azenta in the 4th quarter worth about $110,000. 99.08% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts have issued reports on the company. Evercore ISI upped their target price on Azenta from $50.00 to $52.00 and gave the stock an "in-line" rating in a report on Thursday, February 6th. TD Cowen raised Azenta to a "hold" rating in a report on Thursday, February 27th. Finally, Needham & Company LLC lowered their target price on Azenta from $59.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday, May 7th.
Check Out Our Latest Report on Azenta
Azenta Trading Up 2.8%
AZTA traded up $0.76 on Friday, reaching $27.47. The stock had a trading volume of 882,574 shares, compared to its average volume of 677,258. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -9.22 and a beta of 1.64. The firm has a 50-day moving average of $30.00 and a 200-day moving average of $41.54. Azenta, Inc. has a fifty-two week low of $23.91 and a fifty-two week high of $63.58.
Azenta (NASDAQ:AZTA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.04). Azenta had a negative net margin of 24.91% and a positive return on equity of 1.25%. The firm's quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the firm posted $0.06 earnings per share. Sell-side analysts anticipate that Azenta, Inc. will post 0.53 EPS for the current fiscal year.
Azenta Profile
(
Free Report)
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Read More

Before you consider Azenta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.
While Azenta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.